Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

1.36
-0.2700-16.56%
Post-market: 1.360.00000.00%19:51 EST
Volume:20.38K
Turnover:29.51K
Market Cap:2.30M
PE:-0.08
High:1.60
Open:1.60
Low:1.35
Close:1.63
52wk High:37.50
52wk Low:1.35
Shares:1.69M
Float Shares:1.28M
Volume Ratio:1.00
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.8048
EPS(LYR):-55.8903
ROE:-352.43%
ROA:-120.56%
PB:0.53
PE(LYR):-0.02

Loading ...

Ernexa Therapeutics Adds $5,000 Monthly Cash Compensation for CFO Mark Keeley

Reuters
·
Nov 20

Ernexa Therapeutics Joins Virtual Investor Closing Bell Series Webcast

Reuters
·
Oct 13

Ernexa Says ERNA-101 Preclinical Data Win Flash Talk Slot at Nature-MD Anderson Cancer Meeting

Reuters
·
Oct 06

Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors

Reuters
·
Oct 01

Ernexa Therapeutics CEO Corner Highlights Appointment of DR. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances Erna-101 Toward the Clinic

THOMSON REUTERS
·
Oct 01

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

GlobeNewswire
·
Oct 01

Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101

TIPRANKS
·
Sep 30

Ernexa Targets Q4 2026 IND Filing for First-in-Human ERNA-101 Trial in Platinum-Resistant Ovarian Cancer

Reuters
·
Sep 30

Ernexa Therapeutics - no Teratoma Formation Observed in Erna-101-Treated Animals Through Six-Month Tumorigenicity Phase

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics Reports Compelling Erna-101 Safety Results Across Three Critical Ind-Enabling Studies, Advancing Toward Planned Q4 2026 Ind

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics - Biodistribution Study Shows no Significant Erna-101 Signal in Tumor-Free Animals or Non-Tumor Tissues

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics - Repeat-Dose Glp Toxicology Study Shows no Erna-101-Related Adverse Findings

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

GlobeNewswire
·
Sep 30

Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting

TIPRANKS
·
Sep 29

Ernexa Therapeutics CEO to Present at Cell & Gene Meeting on the Mesa Emerging Track

Reuters
·
Sep 29

Ernexa Therapeutics Director Robert J. Spiegel Files Initial Beneficial Ownership Statement

Reuters
·
Sep 23

Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors

Reuters
·
Sep 17

Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing

THOMSON REUTERS
·
Sep 15